Transfusion Therapy and the Cancer Patient

Acute Care of the Cancer Patient

Volumn , Issue , 2005, Pages 519-536

  Goodnough, Lawrence T ^a   Despotis, George ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247867593     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (145)

1. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Werth J. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The transfusion-transmitted viruses study. N Engl J Med 1981; 304:989-994.
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334:1685-1690.
3. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis F, Notari EP, Petersen LR. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995; 333:1721-1725.
4. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion 1994; 34:471-477.
5. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine, part I. Blood transfusion. N Engl J Med 1999; 340:438-447.
6. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American red cross blood donor population. Transfusion 2002; 42: 975-979.
7. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: Looking to the future. Lancet 2003; 361: 161-169.
8. Joint statement on acquired immune deficiency syndrome (AIDS) related to transfusion. Transfusion 1983; 23:87-88.
9. Silvergleid AJ, Leparc GF, Schmidt PJ. Impact of explicit questions about high-risk activities on donor attitudes and donor referral patterns. Results in two community blood centers. Transfusion 1989; 29: 362-364.
10. Petersen LR, Lackritz E, Lewis W, Smith DS, Herrera G, Raimondi V, Aberle-Grasse J, Dodd RY. The effectiveness of the confidential unit exclusion option. Transfusion 1994; 34:865-869.
11. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA, and The Transfusion Safety Study Group. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991; 31:4-11.
12. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: Opportunities and controversies. Ann Int Med 1997; 127:904-909.
13. Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982-1991. Transfusion 1993; 33:890-893.
14. MMWR Update: HIV-2 infection among blood and plasma donors-United States, June 1992-June 1995. MMWR 1995; 44:603-606.
15. Stramer SL, Grasse JA, Brodsky JP, Busch MP, Lackritz EM. US blood donor screening with p24 antigen (Ag): One year experience. Transfusion 1997; 37(suppl):1S.
16. Domen RE. Paid-versus-volunteer blood donation in the United States: A historical review. Transfusion Med Reviews 1995; 9:53-59.
17. Dodd RY. Adverse consequences of blood transfusion: Quantitative risk estimates. In: Nance ST, ed. Blood Supply: Risks Perceptions, and Prospects for the Future. Bethesda, MD: American Association of Blood Banks, 1994:1-24.
18. Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, Werch J, Edwards V. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients: An analysis of the transfusion-transmitted viruses study. Ann Intern Med 1984; 101:733-738.
19. Alter HJ, Purcell RH, Shih JN, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A and non-B hepatitis. N Eng J Med 1989; 321: 1494-1500.
20. MMWR. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. USHHS. Oct 16, 1998.
21. Conry-Cantilena C, van Raden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, Kaslow R, Ness P, Alter HJ. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691-1696.
22. Tong MJ, El-Farra NS, Reikes AR, Ruth L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-1466.
23. Delwart E, Kalmin N, Jones S, Ladd D, Tobler L, Tsui R, Busch M. First Case of HIV transmission by an RNA-screened blood donation. 9th Conference on Retroviruses and Opportunistic Infections, Feb 24-28, 2002 Washington State Convention and Trade Center, Seattle, WA (http://www.retroconference.org/2002/Posters/13519.pdf).
24. HIV-tainted blood infects two in Florida (http://www.cbsnews.com/stories/2002/07/19/health/main515694.shtml).
25. Da Silva, Cardoso M, Koerner K, Kubanek B. The first case of HCV seroconversion after 3 years of HCV NAT screening in Baden-Wurttemberg. Transfusion 2000; 40(11):1422-1423.
26. Red blood cell transfusions contaminated with Yersinia enterocolitica-United States, 1991-1996, and initiation of a national study to detect bacteriaassociated transfusion reactions. MMWR 1997; 46: 553-555.
27. Cookson ST, Arduino MJ, Aguero SM, Jarvis WR, and The Yersinia Study Group. Yersinia entercoliticacontaminated red blood cells-an emerging threat to blood safety. 1996 Interscience Conference on Antimicrobial Agents and Chemotherapy, ABS New Orieans 1996; 2352.
28. Yomtovian R, Lazarus HM, Goodnough LT, Hirschler NV, Morrissey AM, Jacobs MR. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33:902-909.
29. Leiby DA, Kerr KL, Campos JM, Dodd RY. A retrospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion 1997; 37(3):259-263.
30. Goldman M, Blajchman MA. Blood productassociated bacterial sepsis. Transfus Med Reviews 1991; 5:73-83.
31. AABB. Association Bulletin #96-6. Bacterial contamination of blood components. AABB Faxnet, No 294, August 1996. American Association of Blood Banks.
32. Jacobs MR, Palavecino E, Yomtovian R. Don’t bug me: The problem of bacterial contamination of blood components-challenges and solutions. Transfusion 2001; 41:1331-1334.
33. Ness PM, Braine HG, King K, Barrasso C, Kickler T, Fuller A, Blades N. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41:857-861.
34. Ollgaard M, Albjerg I, Georgen J. Monitoring of bacterial growth in platelet concentrates-one year’s experience with the BactAlertTM System. Vox Sanguinis 1998; 74(suppl 1):1126.
35. Laan E, Tros C. Improved safety and extended shelf-life of leuco-depleted platelet concentrates by automated bacterial screening. Transfusion 1999; 39:5S.
36. Vucetic D, Taseski J, Balint B, Mirovic V. The use of BacTAlert system for bacterial screening in platelet concentrates. Vox Sanguinis 2000; 78(suppl 1):P371.
37. McDonald CP, Roy A, Lowe P, Rogers A, Green G, Vegoda J, Earley J, Barbara JAJ. The first experience in the United Kingdom of the bacteriological screening of platelets to increase shelf life to 7 days. Vox Sanguinis 2000; 78(suppl 1):P375.
38. Brecher ME, Means N, Jere CS, Heath D, Rothenberg S, Stutzman LC. Evaluation of an automated culture systemfor detecting bacterial contamination of platelets: An analysis of 15 contaminating organisms. Transfusion 2001; 41:477-482.
39. AuBuchon JP, Cooper LK, Leach MF, Herschel LH, Roger JC. Bacterial culture of platelet units and extension of storage to 7 days. Transfusion 2001; 41S:1S.
40. Brecher ME, Holland PV, Pineda AA, Tegtmeier GE, Yomtovian R. Growth of bacteria in inoculated platelets: Implications for bacteria detection and the extension of platelet storage. Transfusion 2000; 40: 1308-1312.
41. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-435.
42. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Hogman CF. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sanguinis 2000; 78(4):209-216.
43. Corash L, Behrman B, Rheinschmidt M, Wages D, Snyder E, Raife T, Kagen L, Baril L, Davis K, Metzel P, Walsh J, Smith D, Shafer S, Cimino G, Hei D, Tessman J, Lin L, Buchholz DH. Post-transfusion viability and tolerability of photochemically treated platelet concentrates. Blood 1997; 90:267a.
44. McCullough J, Vesole D, Benjamin RJ, Slichter S, Pineda A, Snyder E. Pathogen-inactivated platelets using HelinxTM technology are hemostatically effective in the thrombocytopenia patient. Blood 2001; 98:45a.
45. Sayers MH, Anderson KC, Goodnough LT, Kurtz SF, Lane TA, Pisciotto P, Silberstein LE. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116:55-62.
46. Rubie H, Attal M, Campardou AM, Gayet-Mengelle C, Payen C, Sanguignol F, Catol JP, Charlet JP, Robert A, Huguet F, Puel J, Pris J, Laurent G. Risk factors for cytomegalovirus in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993; 11:209-214.
47. Bowden RA, Sayers M, Fluornoy N, Newton B, Banaji M, Thomas ED, Meyers JD. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006-1010.
48. Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown R, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101:2067-2069.
49. Wingard JR, Chen DYH, Burns WH, Fuller DJ, Braine HG, Yeager AM, Kaiser H, Burke PJ, Graham ML, Santos GW, Saral R. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71:1432-1437.
50. Verdonck LF, van der Linden JA, Bast BJEG, Meling FGJG, de Gast GC. Influence of cytomegalovirusinfections on the recovery of humoral immunity after autologous bone marrow transplant. Exp Hematol 1987; 15:864-868.
51. Wingard JR, Sostrin MB, Vriessendorp HM, Mellits ED, Santos GW, Fuller DJ, Braine HG, Yeager AM, Burns WH, Saral R. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46:61-65.
52. American Association of Blood Banks. Leukocyte reduction for the prevention of transfusiontransmitted cytomegalovirus (TT-CMV). AABB Bulletin 1997; 17:391.
53. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029-4035.
54. Bowden RA, Slichter SJ, Sayers M, Weidorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV)-seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1985; 86:3598-3603.
55. Ledent E, Berlin G. Inadequate white cell reduction from red cell concentrates by filtration. Transfusion 1994; 34:765-768.
56. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for the prevention of transfusion-associated cytomegalovirus infection. Blood 1996; 87:4910-4911.
57. Adler SP, Baggett J, McVoy M. Transfusionassociated cytomegalovirus infections in seropositive cardiac patients. Lancet 1985; 1:743-746.
58. AABB. VATS study shows no benefit of leukocyte reduction for HIV-Infected patients. AABB Weekly Report 1999; 5:1-2.
59. Lepaucis A, Brown J, Costello B, Delage G, Freedman J, Hume H, King S, Kleinman S, Mazzulli T, Wells G. Prevention of posttransfusion CMV in the era of universal WBC reduction: A consensus statement. Transfusion 2001; 41:560-569.
60. Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfusion Med Reviews 2001; 15:1-20.
61. Luban NLC. Human parvoviruses; implications for transfusion medicine. Transfusion 1994; 34:821-827.
62. Gout O, Baulac M, Gessain A, Semah F, Saal F, Peries J, Cabrol C, Fougault-Fretz C, Laplane D, Sigaux F, de The G. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322:383-388.
63. Kanno M, Nakamura S, Matsuda T. Adult T-cell leukemia with HTLV-I associated myelopathy after complete remission of acute myelogenous leukemia. N Eng J Med 1998; 338:333.
64. Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:786-788.
65. Guerrero IC, Weneger BG, Schultz MG. Transfusion malaria in the United States, 1972-1981. Ann Int Med 1983; 99:221-226.
66. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344:1973-1978.
67. Schmunis GA. Trypanosomo Cruzi, the etiologic agent of Chagas’ disease: Status in the blood supply in endemic and non-endemic countries. Transfusion 1991; 31:547-557.
68. Schmunis GA, Zueker F, Cruz JR, Cuchi P. Safety of blood supply for infectious disease in Latin American countries. Am J Trop Med Hug 2001; 65:924-930.
69. Shulman IA, Appelman S, Saxena S, Hiti AL, Kirchhoff LV. Specific antibodies to Trupansoma cruzi among blood donors in Los Angeles, California. Transfusion 1997; 37:727-731.
70. Cimo PL, Luper WE, Scouroso MA. Transfusionassociated Chagas’ disease in Texas: Report of a case. Tex Med J 1993; 89:48-50.
71. CDC. Chagas disease after organ transplantation. United States, 2001 (http://www.coc.gov/mmwr/preview/mmwrhtm/mm511093.htm).
72. McQuiston JH, Childs JE, Chamberland ME, Tabor E. Transmission of tick-borne agents of disease by blood transfusion: A review of known and potential risks in the United States. Transfusion 2000; 40: 274-284.
73. Brown P, Preece MA, Will RG. Friendly fire in medicine: Hormones, homografts, and Creutzfeldt-Jacob disease. Lancet 1992; 340:24-27.
74. Dodd RY, Sullivan MT. Creutzfeldt-Jacob disease and transfusion safety: Tilting at icebergs? (editorial). Transfusion 1998; 38:221-223.
75. Llewelyn CA, Hewill PE, Knight RW, et al. Possible Transmission of variant creutzfeldt disease by blood transfusion. Lancet 2004; 356:417-419.
76. Revised preventative measures to reduce the possible risk of transmission of CJD and vCJD by blood and blood products (http://www.fda.gov/cber/gdlins/cjdvcjd.htm).
77. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84:1703-1721.
78. Landers DF, Hill GE, Wong KC, Fox IJ. Blood transfusion-induced immunomodulation. Anesth Analg 1996; 82:187-204.
79. Vamvakas EC, Dzik WH, Blajchman MA. Deleterious effects of transfusion-associated immunomodulation: Appraisal of the evidence and recommendations for prevention. In: Vamvakas, ed. Immunomodulatory Effects of Blood Transfusion. Bethesda, MD: AABB Press, 1999:253-285.
80. Lane TA, Anderson KC, Goodnough LT, Kurtz S, Moroff G, Pisciotto PT, Sayers M, Silberstein LE. Leukocyte reduction in blood component therapy. Ann Int Med 1992; 117:151-162.
81. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines on the clinical use of leukocyte-depleted blood components. Transfusion Med 1998; 8:59-71.
82. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible sponge for encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jacob disease in humans. Transfusion 1999; 39: 1169-1178.
83. AABB. PAC recommends universal leukoreduction. AABB Newsbriefs 1998; 20:16.
84. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: What blood component should be given next? Vox Sang 1982; 42:318-321.
85. Chambers LA, Kruskall MS, Pacini DG, Donovan LM. Febrile reactions after platelet transfusion: The effect of single vs. multiple donors. Transfusion 1990; 30:219-221.
86. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869.
87. Goodnough LT, Riddell J, Lazarus H, Chafel TL, Prince G, Hendrix D, Yomtovian R. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65:103-107.
88. Heddle NM, Klama L, Singer J, Richards C, Fedak F, Walker I, Kelton JG. The role of plasma in transfusion reactions. N Engl J Med 1994; 331:625-628.
89. Shiba M, Tadokoro K, Sawanobori M, Nakajima K, Suzuki K, Juji T. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. Transfusion 1997; 37:457-462.
90. Leukoreduction: The techniques used, their effectiveness and costs. Canadian coordinating office for health technology assessment (ECOHTA), 1998 (http://www.ccohta.ca).
91. Uhlmann EJ, Isriggs E, Walher M, Fechtel M, Goodnough LT. Pre-storage universal leukoreduction of RBC does not affect the incidence of transfusion reactions. Transfusion 2001; 41:997-1000.
92. Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I, van Walraven C, Devine D, Sher GD. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289:1941-1949.
93. Dzik WH, Anderson SK, O’Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114-1122.
94. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation -a prospective analysis. Transfusion 1998; 38: 839-847.
95. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G Jr, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA. A multicenter study of platelet recovery and utilization in patients after myeloblative therapy and hematopoietic stem cell transplantation. Blood 1998; 91:3509-3517.
96. Goodnough LT, Kuter D, McCullough J, Brecher ME. Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. J Clin Apher 1998; 13:114-119.
97. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299:799-803.
98. Mowbray JF, Gibbings C, Liddell H, Reginald PW, Underwood JL, Beard RW. Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells. Lancet 1985; 1:941-943.
99. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse? Transfusion 1999; 37:667-670.
100. Ober C, Karrison T, Odem RR, Barnes RB, Branch DW, Stephenson MD, Baron B, Walker MA, Scott JR, Schreiber JR. Mononuclear cell immunization in prevention of recurrentmiscarriages: A randomized trial. Lancet 1999; 354:365-369.
101. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36:175-186.
102. Heiss MM, Mempel W, Delanoff C, Jauch KW, Gabka C, Mempel M, Dieterich HJ, Eissner HJ, Schildberg FW. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12: 1859-1867.
103. Busch OR, Hop WC, van Papendrecht H, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328:1372-1376.
104. Houbiers JG, van de Watering LM, Hermans J, Verwey PJM, Bijnen AB, Pahlplatz P, Schattenkerk ME, Wobbes T, de Vries JE, Klementschlitsch P, van de Maas AHM, van de Velde CJH. Randomized controlled trial comparing transfusion of leukocytedepleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344:573-578.
105. van de Watering LMG, Hermans J, Houbiers JGA, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. A randomized clinical trial. Circulation 1998; 97: 562-568.
106. Hattler BG, Madia C, Johnson C, Armitage JM, Hardesty RL, Kormos RL, Pham SM, Payne DN, Griffith BP. Risk stratification using the Society of Thoracic Surgeons program. Ann Thor Surg 1994; 58:1348-1352.
107. Corwin HL, Aubuchon JP. Is leukoreduction of blood components for everyone? JAMA 2003; 289: 1993-1995.
108. Finch CA, Lenfant C. Oxygen transport in man. N Engl J Med 1972; 286:407-415.
109. Levy PS, Chavez RP, Crystal GJ, Kim SJ, Eckel PK, Sehgal LR, Sehgal HL, Salem MR, Gould SA. Oxygen extraction ratio: A valid indicator of transfusion need in limited coronary reserve?. J Trauma 1992; 32: 769-774.
110. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ. Limit to cardiac compensation during acute isovolemic hemodilution: Influence of coronary stenosis. Am J Physiol 1993; 265:H340-H349.
111. Goodnough LT, Despotis GJ, Hogue CW. On the need for improved transfusion indicators in cardiac surgery. Ann Thor Surg 1995; 60:473-480.
112. Kitchens CS. Are transfusions overrated? Surgical outcome of Jehovah’s Witnesses [Editorial]. Am J Med 1993; 94:117-119.
113. Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, Novecek H, Strom BL. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055-1060.
114. Carson JL, Novock H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hgb levels who decline blood transfusion. Transfusion 2002; 42:812-818.
115. Carson JL, Duff A, Berlin JA, Lawrence VA, Poses RM, Huber EC, O’Hara DA, Noveck H, Strom BL. Perioperative blood transfusion and postoperative mortality. JAMA 1998; 279:199-205.
116. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E, and The Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417.
117. Hebert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? Crit Care Med 2001; 29:227-234.
118. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholtz KM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345:1230-1236.
119. Gore DC, DeMaria EJ, Reines HD. Elevations in red blood cell mass reduce cardiac index without altering the oxygen consumption in severely burned patients. Surg Forum 1992; 43:721-723.
120. Babineau TJ, Dzik WH, Borlase BC, Baxter JK, Bistrian BR, Benotti PN. Reevaluation of current transfusion practices in patients in surgical intensive care units. Am J Surg 1992; 164:22-25.
121. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. N Engl J Med 1990; 323:1781-1788.
122. Rao TLK, Montoya A. Cardiovascular, electrocardiographic and respiratory changes following acute anemia with volume replacement in patients with coronary artery disease. Anesth Dev 1985; 12:49-54.
123. Hogue CW Jr, Goodnough LT, Monk TG. Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy. Transfusion 1998; 38:924-931.
124. ASA Task Force. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on blood component therapy. Anesthesiology 1996; 84:732-747.
125. Welch HG, Mehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Int Med 1992; 116:393-440.
126. NIH. Consensus Conference: perioperative red cell transfusion. JAMA 1988; 260:2700-2703.
127. American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Int Med 1992; 116:403-406.
128. Expert Working Group. Guidelines for red blood cell and plasma transfusions for adults and children. Can Med Assoc J 1997; 156(suppl 11):S1-S24.
129. Weiskopf RB. Efficacy of acute normovolemic hemodilution assessed as a function of fraction of blood volume lost. Anesthesia 2001; 94:439-446.
130. Lenfant C. Transfusion practices should be audited for both undertransfusion and overtransfusion (Letter). Transfusion 1992; 32:873-874.
131. Goodnough LT, Bach RG. Anemia, transfusion, and mortality. N Engl J Med 2001; 345:1272-1274.
132. Wallace EL, Churchill WH, Surgenor DM, An J, Cho G, McGurk S, Murphy L. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35:802-812.
133. Wallace EL, Churchill WH, Surgenor, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998; 38:625-636.
134. National Blood Data Resource Center. Comprehensive Report on Blood Collection and Transfusion in the United States in 2001. Bethesda Maryland, National Blood Data Resource Center 2003.
135. Pall Corp. Demand leukocyte-depleted blood for more complete patient protection. Ann Thor Surg 1997; 60:A20-A21.
136. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersion J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91:3509-3517.
137. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbue T, Mancelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337:1870-1875.
138. Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, Fackler-Schwalbe I, Fischer J, Gackle R, Geer T, Harms P, Loffler B, Ohl S, Otremba B, Raab M, Schonrock-Nabulsi P, Strobel G, Winter R, Link H. Safety and cost effectiveness of a 10 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 109/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601-3606.
139. American Association of Blood Banks. In: Menitove JE, eds. Standards for Blood Banks and Transfusion Services. Bethesda, MD: American Association of Blood Banks, 2002.
140. Goodnough LT, Ali S, Despotis GJ, Dynis M, Dipersio JF. Economic impact of donor platelet count and platelet yield in apheresis products: Relevance for emerging issues in platelet transfusion therapy. Vox Sang 1999; 76:43-49.
141. Hersh JK, Hom EG, Brecher ME. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronic platelet transfusion dependent patient. Transfusion 1998; 38: 637-644.
142. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for fixed platelet requirements. Blood 1985; 66:1105-1109.
143. Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL, Ackerman SJ, Bleeker GC, Mangan KF. Clinical consequences of alterations in platelet transfusion dose: A prospective, randomized double-blind trial. Transfusion 1999; 39:674-681.
144. Norol F, Bierling P, Roudot-Throvac F, Le Coeur FF, Rieux C, Lavaux A, Kuentz M, Deudari N. Platelet transfusion: A dose-response study. Blood 1998; 92:1448-1453.
145. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y. Clinical factors influencing post-transfusion platelet increment in patients undergoing hematopoietic pregenitor cell transplantation -a prospective analysis. Transfusion 1998; 38:839-847.